QuantRx Biomedical Corporation (QTXB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -49.47 Thousand | -74.92 Thousand | -191.67 Thousand | -257.92 Thousand | -150.61 Thousand |
| Net Income | - | -260.04 Thousand | -252.73 Thousand | -621.92 Thousand | -736.85 Thousand | 869.13 Thousand |
| Depreciation & Amortization | - | - | - | - | - | 10.85 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | 210.56 Thousand | 202.42 Thousand | 208.24 Thousand | 210.12 Thousand | 249.14 Thousand |
| Other non-cash items | - | -6.09 | -24.61 Thousand | 222 Thousand | 268.8 Thousand | -1.27 Million |
| Investing Cash Flow | - | - | - | - | 200.58 Thousand | 496.94 Thousand |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | 500 Thousand |
| Other Investing Activities | - | - | - | - | 200.58 Thousand | -3055.00 |
| Financing Cash Flow | - | - | - | - | -80.75 Thousand | 113.08 Thousand |
| Debt repayment | - | - | - | - | -60.75 Thousand | -1912.00 |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | -20 Thousand | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | -60.75 Thousand | 115 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | -6093.00 | -21.3 Thousand | 6611.00 | -12.02 Thousand | 19.72 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | 216.65 Thousand | 223.72 Thousand | 201.63 Thousand | 222.15 Thousand | 229.42 Thousand |
| Cash at beginning of period | 5950.00 | 55.42 Thousand | 130.35 Thousand | 322.02 Thousand | 460.11 Thousand | 691.00 |
| Cash at end of period | 5950.00 | 5950.00 | 55.42 Thousand | 130.35 Thousand | 322.02 Thousand | 460.11 Thousand |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | -49.47 Thousand | -74.92 Thousand | -191.67 Thousand | -138.08 Thousand | 459.42 Thousand |
| Free Cash Flow | - | -49.47 Thousand | -74.92 Thousand | -191.67 Thousand | -257.92 Thousand | -150.61 Thousand |
| Breakdown | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 FY | 2022 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | -61.16 Thousand |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | - | - | 57.4 Thousand |
| Other non-cash items | - | - | - | - | - | 6.26 |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | 6000.00 |
| Debt repayment | - | - | - | - | - | -6000.00 |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | 12 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | 2023.00 |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | 55.38 Thousand |
| Cash at beginning of period | - | - | - | 3884.00 | 5950.00 | 1646.00 |
| Cash at end of period | - | - | - | 3884.00 | 5950.00 | 3884.00 |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | - | - | - | 2238.00 |
| Free Cash Flow | - | - | - | - | - | -3762.00 |
INF
OGE
ASAI
5353
4371
CFRUY